Compare IDEXX Laboratories, Inc. (IDXX) vs Paychex, Inc. (PAYX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Paychex, Inc. — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Paychex, Inc. trades at $104.06 (market cap $37.19B). The key difference: IDEXX Laboratories, Inc. and Paychex, Inc. are close in size by market cap, and Paychex, Inc. pays a 4.56% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Paychex, Inc. for 56 Days on average.
| IDXX | PAYX | |
|---|---|---|
Market Cap | $40.43B | $37.19B |
Volume | 692,164 | 3,344,316 |
Sector | Health | Industrials |
52-Week High | $766.68 | $128.59 |
52-Week Low | $504.70 | $85.57 |
Typical Hold Time | 46 Days | 56 Days |
Enterprise Value | $41.32B | $40.87B |
Dividend Yield | — | 4.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.
The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.
Paychex (PAYX) trades at $103.98, up 2.39% with a bullish technical signal despite mixed indicators. The company demonstrates strong fundamentals with consistent earnings beats, 27.35% net margins, and robust profitability metrics. Recent news highlights investor concerns about dividend sustainability despite solid Q1 2027 results showing 6% revenue growth and double-digit earnings increases driven by PEO and insurance segments.
Outlook remains cautiously optimistic with a $111 consensus price target offering 6.8% upside. Key risks include labor market sensitivity and competitive pressures, while opportunities lie in AI integration and PEO growth. The stock presents a balanced risk-reward profile with dividend stability supporting investor returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →
